University Of Pittsburgh Chosen By NCI As One Of Three Pioneer Sites ForBiocombinatorial Chemistry Research

October 21, 1998

PITTSBURGH, Oct. 21 -- A University of Pittsburgh team of investigators has received a five-year, $5 million federal grant to speed drug discovery through revolutionary means--biocombinatorial chemistry. The National Cancer Institute (NCI) grant to Pittsburgh researchers is one of only three issued nationwide. Biocombinatorial chemistry is an emerging field characterized by the rapid, parallel synthesis of large "libraries" of organic compounds used for testing in biological systems.

This initiative, conceived to discover new cancer drugs, is a combined effort by researchers from the School of Medicine's department of pharmacology, the university's department of chemistry, the Graduate School of Public Health's department of environmental and occupational health and a private Pittsburgh-based company, Cellomics, Inc. Through biocombinatorial chemistry, the university investigators will create novel chemical compounds at the department of chemistry's newly established Combinatorial Chemistry Center and then test them elsewhere in the university in specific assays to learn whether they interrupt cellular activities that can lead to cancer. Pittsburgh researchers also will create a repository for newly manufactured compounds that then can be acquired and tested by outside investigators.

"The University of Pittsburgh is at the academic forefront of a creative revolution in drug manufacturing," said Ronald B. Herberman, M.D., director of the University of Pittsburgh Cancer Institute (UPCI) and associate vice chancellor for research, Health Sciences, University of Pittsburgh. "UPCI is benefiting enormously from a unique, integrated group of exceptional laboratory and clinical investigators. Together, they are developing and executing 21st-century approaches to translating basic research into the clinic.

"Everyday, scientists are discovering the molecular bases of disease and, in the process, revealing many new potential drug targets. Biocombinatorial chemistry is the most comprehensive approach to designing highly specific drugs that work," said John S. Lazo, Ph.D., principal investigator on the grant, Allegheny Foundation professor and chairman of the university's department of pharmacology and co-director of UPCI's Molecular Therapeutics/Drug Discovery program. "Biocombinatorial chemistry offers a stark contrast to current methods of drug discovery, which have a long lag time from drug synthesis to application in the clinic with patients. By contrast, biocombinatorial chemistry is expected to offer the public optimally effective, safe medications quickly," he added.

Biocombinatorial chemistry exploits the discovery of genes and their proteins, which serve as molecular targets for drugs because they control biological processes that often lead to disease.

"With this approach, we start with a chemical compound called a platform that locks onto a specific molecular target. We change the platform incrementally to quickly produce hundreds of compounds that we can screen against that given target," said Peter Wipf, Ph.D., co-investigator on the grant and professor in the department of chemistry, where he directs the Combinatorial Chemistry Center. "Through this process, we can readily learn what specific compound structure is best at disrupting a biological pathway."

"Biocombinatorial chemistry has particular importance for diseases like cancer, where you want to provide a highly specific drug that will effectively and selectively kill tumor cells without damaging other healthy cells and potentially creating dangerous side effects," added Dr. Lazo.

This new approach to drug discovery combines university expertise in genomics (the discovery and classification of new genes), chemical design and synthesis, biochemistry, pharmacology, toxicology, computer modeling and robotics with expertise from faculty at Carnegie Mellon University.

The UPCI is one of a select group of NCI-designated comprehensive cancer centers nationwide. As such, it excels in patient care and in cancer detection, diagnosis, prevention and treatment. UPCI is internationally recognized for bringing laboratory research findings to the clinic where patients have the advantage of exceptional treatment opportunities.

rmc/10-21-98
-end-


University of Pittsburgh Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.